Published on January 26, 2017
John Gribben, MD, DSc, FRCPath, FMed Sci from Bart's Cancer Institute, London, discusses how Chronic Lymphocytic Leukemia (CLL) clinical trials have changed over time. Today, trials involve treatments that are known to be beneficial to patients and novel agents tend to be trialled in combination to improve patient response whilst not increasing toxicity. Recorded at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.
This program has been supported by AbbVie through an unrestricted grant to the Patient Empowerment Foundation.